Wolfgang Miesbach/LinkedIn
Apr 23, 2026, 03:17
Wolfgang Miesbach: The Haemophilia A Gene Therapy Story Is Moving from West to China
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”The haemophilia A gene therapy story is not over – it is moving from West to China:
West: BioMarin is withdrawing Roctavian from the global market after failing to divest the product, marking a major commercial retreat from this first‑in‑class AAV5 FVIII gene therapy.
China: GS1191‑0445 (AAV8, liver-directed) continues to advance, with new multi‑year data in 76 adults with severe haemophilia A presented by Dr. Wei Liu at WFH 2026.
- Doses: 2×10¹²–4×10¹² vg/kg
- Mean FVIII:C approximately 45 IU/dL at 2 years (3×10¹² vg/kg)
- ABR reduced by up to 99.4% vs baseline
- Zero spontaneous bleeds over 52 weeks at 3×10¹² and 4×10¹²
- No thrombotic events, no inhibitors; TEAEs mostly grade 1–2 under prophylactic prednisone plus tacrolimus
Durable multi‑year expression and near‑elimination of bleeding remain realistic goals.”
Stay updated with Hemostasis Today.
-
Sep 8, 2026, 16:14Heghine Khachatryan: Colombo 2026 Insights on Point-of-Care Ultrasound in Hemophilia Joint Care
-
Sep 8, 2026, 15:57Flora Peyvandi: Efficiency Meets Innovation in Hemophilia B Gene Therapy
-
Sep 8, 2026, 15:48Maxime Dely: Guillain-Barré Syndrome – What if the Key Lies in the Plasma?
-
Sep 8, 2026, 15:34Ron DePinho: A Negative Trial Highlights the Need for Precision in Cardiovascular Inflammation
-
Sep 8, 2026, 15:31Adil Yousaf: Thrombolysis Speed Matters, but Eligibility Comes First
-
Sep 8, 2026, 15:28Dhargam Aljebouri: First Molecularly Characterized Para-Bombay Phenotype in the Arab World
-
Sep 8, 2026, 15:27Mohd Ashhad: How Much Does Hemoglobin Increase After 1 Unit of PRBC?
-
Sep 8, 2026, 15:27Sanish Babu: The Hematocrit–Platelet Signal in Severe Dengue
-
Sep 8, 2026, 15:26Mary Kama: Climate-Informed Early Warning Systems for Sickle Cell Anaemia